Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Radiprodil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 9/20 | 1.00 |
| ▸ | GRIN2B known ✓ | Q13224 | 9/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 7/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 7/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 7/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 7/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radiprodil SCHEMBL99256 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| Radiprodil SCHEMBL134435 | 0.99 | GRIN1 (0.98) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| Radiprodil SCHEMBL135546 | 0.99 | GRIN1 (0.98) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4577953 | 0.93 | GRIN1 (0.86) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4576956 | 0.92 | GRIN1 (0.84) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4412049 | 0.91 | GRIN1 (0.83) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4414151 | 0.91 | GRIN1 (0.83) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4550674 | 0.91 | GRIN1 (0.83) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL2264133 | 0.91 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4578785 | 0.90 | GRIN1 (0.82) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478618-B1 | Use of glutamate 2B receptor antagonists and sigma receptor agonists as antitussives | SEYLTX, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2025202421-A1 | METHODS AND COMPOSITIONS | VRG 145 ZRT. (HU) | 2025-10-02 | — | — | WO | disclosed |
| EP-4051276-A1 | USE OF GLUTAMATE 2B RECEPTOR ANTAGONISTS AND SIGMA RECEPTOR AGONSISTS AS ANTITUSSIVES | Algernon Pharmaceuticals Inc. (CA) | 2022-09-07 | — | — | EP | disclosed |
| CN-114585364-A | Use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives | 阿尔杰农制药股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478618-B1 | Use of glutamate 2B receptor antagonists and sigma receptor agonists as antitussives | GRIN2B, HTR2B, GRM1 | GRIN1 45/4885GRIN2B 1/4885GRIN2D 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.